Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%)
Form 8-K Table 3a / 3b Product Sales
Latest, FY2018
-99.0%
Period ended Dec 31, 2018
Change on a year earlier
-157.0 pts
58.0% in FY2017
History
2 years
Since FY2017
Sources
2
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2018 | Dec 31, 2018 | -99.0% | -157.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 58.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%), annual FY2017–FY2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_zepatier_us_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.